Search Follow us


Following positive data from its first Ocular Bandage Gel (OBG) pilot study, EyeGate has filed an amended Investigational Device Exemption (IDE) application with the FDA for a second trial. If accepted, the OBG may return to human trials in Q218. Data readouts from the trials in H218 in addition to the ongoing Phase III study for EGP-437 could prompt key value inflection drivers.

Continue reading

This version is programmatically created by Responsive Labs and qualified in its entirety to the original PDF.

Powered by Responsive Labs